

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP	
<b>2. Address</b> Address1 1800 CONCORD PIKE, P.O. BOX 15437 Address2 _____ City WILMINGTON State DE Zip Code 19850-5437 Country USA	
<b>3. Principal place of business (if different than line 2)</b> City _____ State _____ Zip Code _____ Country _____	
4a. Contact Name Ms. Jamie Bell	b. Telephone Number 2023505550
c. E-mail jamie.bell@astrazeneca.com	
5. Senate ID# 54073-12	
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP	
6. House ID# 349750000	

## TYPE OF REPORT

8. Year 2019 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity

## INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

<p><b>12. Lobbying</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSE</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>450,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>
--	--

Signature Digitally Signed By: Jamie Bell

Date 10/20/2019  
8:36:09 PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- Value of Prescription Drugs
- Drug Pricing Transparency
- Oncology Care Model
- Personalized Medicine
- Diagnostics
- S. 1895, Lower Health Care Costs Act
- HR 3 drug pricing bill

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Natalie	Morris			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Morgan	Bradley-Jones			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Julie	Garner			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

- Medicare Part D Coverage and Reimbursement
- Medicare Part D Non-Interference
- Legislative proposals to change Medicare Part D; Rebate Rule
- Medicare Part B coverage and reimbursement
- Changes to the Medicaid Drug Rebate Program (AMP Cap)
- Medicare Part B Intl. Pricing Index ANPRM
- 14 Day Rule
- End State Renal Disease PPS
- Senate Finance drug pricing package
- HR 3 drug pricing bill

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Natalie	Morris			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Morgan	Bradley-Jones			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Julie	Garner			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- Medicare Part D coverage and reimbursement
- Value of Prescription Drugs
- Prescription Drug Importation
- Innovative Payment Models
- Price Transparency
- Legislative proposals to change Medicare Part D
- Medicaid and 340B issues & drug discount program
- President’s Drug Pricing Blueprint
- H.R. 1499, Protecting Consumer Access to Generic Drugs Act
- S. 1416, Affordable prescriptions for Patients Act
- S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Natalie	Morris			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Morgan	Bradley-Jones			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Julie	Garner			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

<ul style="list-style-type: none"> <li>• FDA Patent Settlement legislation</li> <li>• Intellectual property and patent issues</li> <li>• S. 340, H.R. 965 CREATES Act</li> <li>• S. 1209, REMEDY Act</li> <li>• S. 1224, H.R. 2374, Stop STALLING Act</li> </ul>
--

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
--

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Morgan	Bradley-Jones			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Natalie	Morris			<input type="checkbox"/>
Julie	Garner			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

--

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

---

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1			3		
2			4		

---

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

--	--	--	--	--	--	--	--	--

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address City	State/Province	Zip	Country	City State	Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1	2	3
---	---	---

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address City	State/Province	Country			
				City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1	3	5
2	4	6

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------